Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6% – Should You Sell?
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
BioAge Announces Proposed Public Offering
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
BioAge Labs to Present at Upcoming Investor Conferences
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. Lawsuit - BIOA
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BIOA
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
Shareholders that Lost Money on BioAge Labs, Inc. (BIOA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIOA
Investors Who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Shareholders that Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA